|
1
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29 (6 Suppl 16):S15–S18. 2002.
View Article : Google Scholar
|
|
2
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aalders KC, Tryfonidis K, Senkus E and
Cardoso F: Anti-angiogenic treatment in breast cancer: Facts,
successes, failures and future perspectives. Cancer Treat Rev.
53:98–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo
Y, Ren D, Hua Y, Yu B, Zhou Y, et al: Mechanisms of vasculogenic
mimicry in hypoxic tumor microenvironments. Mol Cancer. 20:72021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Williamson SC, Metcalf RL, Trapani F,
Mohan S, Antonello J, Abbott B, Leong HS, Chester CP, Simms N,
Polanski R, et al: Vasculogenic mimicry in small cell lung cancer.
Nat Commun. 7:133222016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirakawa K, Tsuda H, Heike Y, Kato K,
Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, et
al: Absence of endothelial cells, central necrosis, and fibrosis
are associated with aggressive inflammatory breast cancer. Cancer
Res. 61:445–451. 2001.PubMed/NCBI
|
|
8
|
Wagenblast E, Soto M, Gutiérrez-Ángel S,
Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY,
Dickopf S, et al: A model of breast cancer heterogeneity reveals
vascular mimicry as a driver of metastasis. Nature. 520:358–362.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z
and Zhou Q: Tumour vasculogenic mimicry is associated with poor
prognosis of human cancer patients: A systemic review and
meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang JP, Liao YD, Mai DM, Xie P, Qiang YY,
Zheng LS, Wang MY, Mei Y, Meng DF, Xu L, et al: Tumor vasculogenic
mimicry predicts poor prognosis in cancer patients: A
meta-analysis. Angiogenesis. 19:191–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Zong S, Shi Q, Li H, Xu J and Hou F:
Hypoxia-induced vasculogenic mimicry formation in human colorectal
cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and
Vimentin. Sci Rep. 6:375342016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu
F, Zhang Y, Dong X and Sun B: HIF-1α promoted vasculogenic mimicry
formation in hepatocellular carcinoma through LOXL2 up-regulation
in hypoxic tumor microenvironment. J Exp Clin Cancer Res.
36:602017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol. 2:737–744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng J, Chen S, Lei YY, Han JX, Zhong WL,
Wang XR, Liu YR, Gao WF, Zhang Q, Tan Q, et al: Hsp90β promotes
aggressive vasculogenic mimicry via epithelial-mesenchymal
transition in hepatocellular carcinoma. Oncogene. 38:228–243. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai HP, Wang J, Xi SY, Ni XR, Chen YS, Yu
YJ, Cen ZW, Yu ZH, Chen FR, Guo CC, et al: Tenascin-c mediated
vasculogenic mimicry formation via regulation of MMP2/MMP9 in
glioma. Cell Death Dis. 10:8792019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang YH, Teichert U and Smith JA:
Molecular cloning, sequencing, deletion, and overexpression of a
methionine aminopeptidase gene from Saccharomyces cerevisiae. J
Biol Chem. 267:8007–8011. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X and Chang YH: Amino-terminal protein
processing in Saccharomyces cerevisiae is an essential function
that requires two distinct methionine aminopeptidases. Proc Natl
Acad Sci USA. 92:12357–12361. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Datta B, Chakrabarti D, Roy AL and Gupta
NK: Roles of a 67-kDa polypeptide in reversal of protein synthesis
inhibition in heme-deficient reticulocyte lysate. Proc Natl Acad
Sci USA. 85:3324–3328. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCowen MC, Callender ME and Lawlis JF Jr:
Fumagillin (H-3), a new antibiotic with amebicidal properties.
Science. 113:202–203. 1951. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ingber D, Fujita T, Kishimoto S, Sudo K,
Kanamaru T, Brem H and Folkman J: Synthetic analogues of fumagillin
that inhibit angiogenesis and suppress tumour growth. Nature.
348:555–557. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kusaka M, Sudo K, Matsutani E, Kozai Y,
Marui S, Fujita T, Ingber D and Folkman J: Cytostatic inhibition of
endothelial cell growth by the angiogenesis inhibitor TNP-470
(AGM-1470). Br J Cancer. 69:212–216. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann
WG and Crews CM: The anti-angiogenic agent fumagillin covalently
binds and inhibits the methionine aminopeptidase, MetAP-2. Proc
Natl Acad Sci USA. 94:6099–6103. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Griffith EC, Su Z, Turk BE, Chen S, Chang
YH, Wu Z, Biemann K and Liu JO: Methionine aminopeptidase (type 2)
is the common target for angiogenesis inhibitors AGM-1470 and
ovalicin. Chem Biol. 4:461–471. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeh JJ, Ju R, Brdlik CM, Zhang W, Zhang Y,
Matyskiela ME, Shotwell JD and Crews CM: Targeted gene disruption
of methionine aminopeptidase 2 results in an embryonic gastrulation
defect and endothelial cell growth arrest. Proc Natl Acad Sci USA.
103:10379–10384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Catalano A, Romano M, Robuffo I, Strizzi L
and Procopio A: Methionine aminopeptidase-2 regulates human
mesothelioma cell survival: Role of Bcl-2 expression and telomerase
activity. Am J Pathol. 159:721–731. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Selvakumar P, Lakshmikuttyamma A, Kanthan
R, Kanthan SC, Dimmock JR and Sharma RK: High expression of
methionine aminopeptidase 2 in human colorectal adenocarcinomas.
Clin Cancer Res. 10:2771–2775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tucker LA, Zhang Q, Sheppard GS, Lou P,
Jiang F, McKeegan E, Lesniewski R, Davidsen SK, Bell RL and Wang J:
Ectopic expression of methionine aminopeptidase-2 causes cell
transformation and stimulates proliferation. Oncogene.
27:3967–3976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Sheppard GS, Lou P, Kawai M,
BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC,
et al: Tumor suppression by a rationally designed reversible
inhibitor of methionine aminopeptidase-2. Cancer Res. 63:7861–7869.
2003.PubMed/NCBI
|
|
29
|
Van der Schaft DW, Seftor RE, Seftor EA,
Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW and
Hendrix MJ: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kawahara R, Niwa Y and Simizu S: Integrin
β1 is an essential factor in vasculogenic mimicry of human cancer
cells. Cancer Sci. 109:2490–2496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ran FA, Hsu PD, Wright J, Agarwala V,
Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9
system. Nat Protoc. 8:2281–2308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Simizu S, Umezawa K, Takada M, Arber N and
Imoto M: Induction of hydrogen peroxide production and Bax
expression by caspase-3(−like) proteases in tyrosine kinase
inhibitor-induced apoptosis in human small cell lung carcinoma
cells. Exp Cell Res. 238:197–203. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yasukagawa T, Niwa Y, Simizu S and Umezawa
K: Suppression of cellular invasion by glybenclamide through
inhibited secretion of platelet-derived growth factor in ovarian
clear cell carcinoma ES-2 cells. FEBS Lett. 586:1504–1509. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Komai K, Niwa Y, Sasazawa Y and Simizu S:
Pirin regulates epithelial to mesenchymal transition independently
of Bcl3-Slug signaling. FEBS Lett. 589:738–743. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Katsuyama S, Sugino K, Sasazawa Y, Nakano
Y, Aono H, Morishita K, Kawatani M, Umezawa K, Osada H and Simizu
S: Identification of a novel compound that inhibits
osteoclastogenesis by suppressing nucleoside transporters. FEBS
Lett. 590:1152–1162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ishida K, Wierzba MK, Teruya T, Simizu S
and Osada H: Novel heparan sulfate mimetic compounds as antitumor
agents. Chem Biol. 11:367–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Simizu S, Imoto M and Umezawa K: Induction
of apoptosis by erbstatin in mouse leukemia L1210 cells. Biosci
Biotechnol Biochem. 58:1549–1552. 1994. View Article : Google Scholar
|
|
39
|
Griffith EC, Su Z, Niwayama S, Ramsay CA,
Chang YH and Liu JO: Molecular recognition of angiogenesis
inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.
Proc Natl Acad Sci USA. 95:15183–15188. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Delgado-Bellido D, Serrano-Saenz S,
Fernández-Cortés M and Oliver FJ: Vasculogenic mimicry signaling
revisited: Focus on non-vascular VE-cadherin. Mol Cancer.
16:652017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Datta B, Majumdar A, Datta R and Balusu R:
Treatment of cells with the angiogenic inhibitor fumagillin results
in increased stability of eukaryotic initiation factor 2-associated
glycoprotein, p67, and reduces phosphorylation of extracellular
signal-regulated kinases. Biochemistry. 43:14821–14831. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Datta B and Datta R: Mutation at the
acidic residue-rich domain of eukaryotic initiation factor 2
(eIF2alpha)-associated glycoprotein p67 increases the protection of
eIF2alpha phosphorylation during heat shock. Arch Biochem Biophys.
413:116–122. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Datta B, Ghosh A, Majumdar A and Datta R:
Autoproteolysis of rat p67 generates several peptide fragments: The
N-terminal fragment, p26, is required for the protection of
eIF2alpha from phosphorylation. Biochemistry. 46:3465–3475. 2007.
View Article : Google Scholar : PubMed/NCBI
|
